TITLE

Hepatitis A vaccination in chronic liver disease: is it really required in a tropical country like India?

AUTHOR(S)
Joshi, N.; Rao, S.; Kumar, A.; Patil, S.; Rani, S.
PUB. DATE
April 2007
SOURCE
Indian Journal of Medical Microbiology;Apr2007, Vol. 25 Issue 2, p137
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Vaccination against hepatitis A virus (HAV) has been recommended in patients with chronic liver disease to prevent any decompensation due to superinfection. This may not hold good in high endemic areas for hepatitis A like India. The aim of this study was to find out the seroprevalence of anti-HAV antibodies in patients with chronic liver disease and to justify the need for vaccination against hepatitis A virus in these patients. One hundred and thirty three consecutive patients with cirrhosis of liver attending Gastroenterology department of our Institute between June 2004 and June 2005 were enrolled. Seventy-five healthy persons were taken as controls. The diagnosis of cirrhosis was based on clinical profile, biochemical, radiological (ultrasound abdomen) and endoscopic findings. The etiology of cirrhosis was based on presence of viral markers, history of significant alcohol consumption, autoimmune and metabolic workup. All patients and controls were tested for antiHAV (total) antibodies using commercially available enzyme-linked immunosorbent assay kits. Data from patients and control group were compared by unpaired 't' test and Chi square test. All subjects were in the age group 11 to 75 years. Etiology of chronic liver disease was as follows: HBV- 29.3%, HCV - 14.28%, HBV+HCV dual -1.5%, alcohol- 21.8%, Cryptogenic -23.3%, Wilson"s Disease -1.5% and Budd chiari -1.5%. The prevalence of HAV was 93.2% in patients with cirrhosis of liver and 94.6% in controls. The prevalence was almost similar irrespective of the etiology. In view of high seroprevalence of HAV antibodies among cirrhotic patients in our study and the high cost of the vaccine, the hepatitis A vaccination may not be routinely required in this part of the world.
ACCESSION #
26050582

 

Related Articles

  • Hepatitis A – The Price of Progress. Di Giammarino, Loriana; Dienstag, Jules L. // New England Journal of Medicine;9/1/2005, Vol. 353 Issue 9, p944 

    The article presents information on Hepatitis A in the U.S. According to a report, hepatitis A is not a cause of chronic liver diseases like hepatitis B and hepatitis C. It is a self-limited disease with a low case fatality rate. In the U.S. it is a common cause of acute hepatitis and one of the...

  • Approach to Clinical Syndrome of Jaundice and Encephalopathy in Tropics. Anand, Anil C.; Garg, Hitendra K. // Experimental & Clinical Hepatology;Mar2015, Vol. 5 Issue S1, pS116 

    A large number of patients present with jaundice and encephalopathy in tropical country like India and acute liver failure is the usual cause. Clinical presentation like ALF is also a complication of many tropical infections, and these conditions may mimic ALF but may have subtle differences...

  • Evaluation of Albanian Immunization Program with Hepatitis B vaccine. NELAJ, ERIDA; LIKA (ÇEKANI), MIRELA; BINO, SILVA // Albanian Journal of Agricultural Sciences;2013, Vol. 12 Issue 2, p315 

    There are about 150 million carriers of hepatitis B virus all over the world, most of whom are unaware that they are carriers. Most babies born to mothers who are carriers also become carriers. About 25% of untreated babies who are infected with hepatitis B virus subsequently develop severe...

  • Hepatitis A prophylaxis for liver patients.  // Modern Medicine;Sep97, Vol. 65 Issue 9, p43 

    Reports that an inactivated Hepatitis A vaccine from SmithKline Beecham has been approved for prevention of Hepatitis A in persons who have chronic liver disease.

  • Hepatitis A, B vaccinations low in patients with chronic liver disease, diabetes. Friedman, Lawrence S. // Infectious Disease News;Jun2011, Vol. 24 Issue 6, p8 

    The article reports on a study which revealed that hepatitis A and hepatitis B vaccinations are low in patients with chronic liver disease and in those with type 2 diabetes.

  • Prevalence of Hepatitis C and B Viral Markers in Patients with Chronic Liver Disease: A Study from Northern India. Chakravarti, A.; Verma, V. // Indian Journal of Medical Microbiology;Oct2005, Vol. 23 Issue 4, p273 

    A letter to the editor regarding the prevalence of hepatitis C and B viral markers in patients with chronic liver disease in India, is presented.

  • Is Hepatitis A More Severe in Patients with Chronic Hepatitis B and Other Chronic Liver Diseases? Keeffe, Emmet B. // American Journal of Gastroenterology;Feb1995, Vol. 90 Issue 2, p201 

    There are several published case series of acute hepatitis A, with coverage ranging from epidemics to case reports, that provide information regarding the clinical course and outcome of hepatitis A in patients with underlying chronic hepatitis B virus (HBV) infection (1-12). Only a few reports...

  • Antiviral Therapy for Chronic Hepatitis B: A Review. Hanazaki, Kazuhiro // Current Drug Targets - Inflammation & Allergy;Mar2004, Vol. 3 Issue 1, p63 

    Chronic hepatitis B virus (HBV) infection is a well-recognized risk factor for the development of hepatocellular carcinoma (HCC), which is becoming a more prevalent clinical problem, especially in HBV-endemic areas. It is estimated that 1.25 million people in the United States and more than 300...

  • Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of Liver. Roni, D. Ajith; Pathapati, Rama Mohan; Kumar, A. Sathish; Nihal, Lalit; Sridhar, K.; Rajashekar, Sujith Tumkur // Advances in Virology;2013, p1 

    Introduction. Patients with chronic liver disease (CLD) are more likely to have severe morbidity and fatality rate due to superimposed acute or chronic hepatitis B (HBV) infection. The literature has shown that hepatitis B vaccines are safe and effective in patients with CLD, but the data in...

  • Treatment of subacute hepatitis B with lamivudine: a pilot study in Serbia. Delić, Dragan; Nešić, Zorica; Prostran, Milica; Boričić, Ivan; Svirtlih, Neda // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Mar2009, Vol. 66 Issue 3, p199 

    Background/Aim. The incidence of acute hepatitis B viral (HBV) infection in adults has increased in recent years in Serbia. Most icteric patients with acute hepatitis B resolve their infection and do not require treatment. Fulminant hepatitis B is a severe form of acute infection complicated by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics